摘要:
A package for storing an aerosolizable pharmaceutical formulation comprises a capsule adapted to contain the aerosolizable pharmaceutical formulation, and a moisture barrier around the capsule. The moisture barrier comprises a material that is resistant to moisture passage, whereby the moisture barrier reduces the amount of moisture in contact with the aerosolizable pharmaceutical formulation so that the aerosolizable pharmaceutical formulation may be aerosolized when the capsule is opened. In one version, the moisture barrier comprises a metal.
摘要:
The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.
摘要翻译:本发明提供了编码粳稻主要花粉过敏原Cryj I,Cryj II,Jun s I和Jun v I的核酸序列及其片段或肽。 本发明还提供纯化的Cry j I,Cryj II,Jun s I和Jun v I,以及在用编码Cryj I,Cryj II,Jun的核酸序列转化的宿主细胞中产生的至少一个片段 I和Jun v I或其至少一个片段,以及Cry j I,Cry j II,Jun s I或Jun v I或其至少一个片段的片段,以及Cryj I,Cryj II,Jun 我或Jun v我合成了。 Cry j I,Cry j II,Jun s I和Jun v I及其片段可用于诊断,治疗和预防日本雪松花粉病。 本发明还提供了Cryj I和Cryj II的分离的肽。 本发明范围内的肽包含至少一个T细胞表位,或优选至少两个Cryj I或Cryj II的T细胞表位。 本发明还涉及与相应的天然存在的变应原或其部分具有相似或增强的治疗性质但具有减少的副作用的改性肽。 还提供了治疗或诊断个体对日本雪松花粉和治疗组合物的方法,以及包含一种或多种本发明的肽的多肽制剂。
摘要:
Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
摘要:
Isolated nucleic acids encoding an allergen of Dermatophagoides pteronyssinus, Der p III, are disclosed. A cDNA encoding a peptide having a Der p III activity and a predicted molecular weight of about 24,985 daltons is also described. The nucleic acids can be used as probes to detect the presence of Der p III nucleic acid in a sample or for the recombinant production of peptides having an activity of Der p III. Peptides having an activity of Der p III can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites.
摘要翻译:公开了编码Dermatophagoides pteronyssinus,Der p III的变应原的分离的核酸。 还描述了编码具有Der p III活性和约24,985道尔顿的预测分子量的肽的cDNA。 核酸可以用作探针,以检测样品中Der p III核酸的存在或重组产生具有Der p III活性的肽。 具有Der p III活性的肽可用于适用于药物施用的组合物或诊断对尘螨敏感性的方法。
摘要:
Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
摘要:
An aerosolization system includes a squeezable container having a resilient container body. The container is configured to deliver a unit dosage of a liquid when squeezed a single time. The system also includes an aerosolizer that is constructed of a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator comprises a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.
摘要:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
摘要:
An aerosolization system includes a squeezable container having a resilient container body. The container is configured to deliver a unit dosage of a liquid when squeezed a single time. The system also includes an aerosolizer that is constructed of a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator includes a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.
摘要:
Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.
摘要:
The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.